Outlook Therapeutics, Inc.
NASDAQ: OTLK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Charles Jahr
- Employees
- 23
- Headquarters
- Iselin, United States
- IPO year
- 2016
- Market cap
- $69.1M
- Website
- https://www.outlooktherapeutics.com
Loading OTLK…
Loading profile data…Frequently asked questions about OTLK
What does Outlook Therapeutics, Inc. (OTLK) do?
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials....
Where does OTLK trade?
Outlook Therapeutics, Inc. (OTLK) trades on the NASDAQ Capital Market.
What sector is OTLK in?
Outlook Therapeutics, Inc. (OTLK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Outlook Therapeutics, Inc.?
Robert Charles Jahr is the chief executive officer of Outlook Therapeutics, Inc. (OTLK).
Where is Outlook Therapeutics, Inc. headquartered?
Outlook Therapeutics, Inc. is headquartered in United States.
Does OTLK pay a dividend?
Outlook Therapeutics, Inc. (OTLK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did OTLK go public?
Outlook Therapeutics, Inc. (OTLK) completed its initial public offering in 2016.